Hester receives manufacturing license for Inactivated Avian Influenza Vaccine for poultry

Hester Biosciences Limited has received the manufacturing license from the Food & Drugs Control Administration to manufacture and market the Low Pathogenic Avian Influenza Vaccine, Inactivated H9N2 strain for poultry.

Low Pathogenic Avian Influenza H9N2 strain has been a persistent challenge in poultry flocks and is known to cause year-round comorbidity, leading to significant economic losses. H9N2 can lead to an irreversible drop in egg production in layers and performance loss in broilers. It can also lead to high mortality in the presence of other infections.

This license is a key regulatory milestone in advancing Hester’s prevention-led poultry healthcare portfolio.

This vaccine has been developed from technology acquired from ICAR-NIHSAD via Agrinnovate India.

(Disclosures: At the time of writing this article, author, his clients & dependent family members may have positions in the stocks mentioned above. The author, his firm, his clients or any of his dependent family members may make purchases or sale of the securities mentioned in website. Author may have positions in above stocks so have vested interest obviously in their going up or down as the case may be.

Disclaimer: Investing in any equity is risky. Our recommendations are based on reliable & authenticated sources believed to be true & correct, and also is technical analysis based on & conceived from charts. Investors should take their own decisions. We assume no responsibility for any transactions undertaken by them. The author won't be liable or responsible for any legal or financial losses made by anybody. Investors must take advice from their financial advisors before investing in any stocks.)